Status:
TERMINATED
Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Breast Neoplasms
Eligibility:
FEMALE
18+ years
Phase:
PHASE4
Brief Summary
This study will evaluate the safety/efficacy of zoledronic acid when given by intravenous infusion every 4 weeks in addition to letrozole as endocrine therapy in postmenopausal patients with hormone r...
Detailed Description
Open-label, multicenter, randomized phase II trial over approx 6.5 months of neoadjuvant treatment with letrozole with or without zoledronic acid in postmenopausal patients with primary breast cancer....
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Postmenopausal women with primary invasive breast cancer, histologically confirmed by core needle biopsy, whose tumors are estrogen (ER) and / or progesterone (PgR) positive
- Clinical Stage T1c (Size ≥ 1.5 cm), T2, T3, T4a, b, c, N0 or N1, M0 (TNM Classification). According to the modified RECIST criteria, tumors of size ≥ 1.5 cm are considered measurable by mammography and can be determined as target lesions).
- Tumor measurable by mammography, sonography and clinical examination.
- Adequate bone marrow, renal and hepatic function
- Good health status (ECOG Performance status of 0, 1 or 2)
- Exclusion criteria:
- Prior treatment with letrozole or bisphosphonates. Prior and concomitant anti-breast-cancer treatments such as chemotherapy, immunotherapy / biological response modifiers (BRM's), endocrine therapy other than letrozole (including steroids), and radiotherapy. Patients who have received hormone replacement therapy (HRT) will NOT be excluded, provided that HRT is discontinued at least 2 weeks prior to entry into the study.
- Patients with unstable angina, or uncontrolled cardiac disease (e.g. Class III and IV New York Heart Association's Functional Classification, see Appendix 9) or uncontrolled endocrine disorders.
- Evidence of inflammatory breast cancer or distant metastasis.
- Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures. Recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants).
- History of diseases with influence on bone metabolism, such as Paget's disease, Osteogenesis Imperfecta, and primary or secondary hyperthyroidism within the 12 months prior to study entry
- Other protocol-defined inclusion/exclusion criteria may apply
Exclusion
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 16 2010
Estimated Enrollment :
168 Patients enrolled
Trial Details
Trial ID
NCT00375752
Start Date
June 1 2006
End Date
December 16 2010
Last Update
June 26 2017
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Amberg, Germany, 92224
2
Novartis Investigative Site
Berlin, Germany, 10365
3
Novartis Investigative Site
Böblingen, Germany, 71032
4
Novartis Investigative Site
Celle, Germany, 29223